The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...